Forecast

The analysts' average price target is €169.00 (+56.45%). The median is €167.41 (+54.98%).

Buy	33
Hold	1
Sell	1

News Go to news feed

Insmed flagged as largest detractor by Artisan despite strong Brinsupri launch

Artisan Global Opportunities said Insmed was its biggest detractor in Q2 after trimming the position, citing Q1 sales modestly below elevated expectations due to concerns around discontinuation, therapy continuation and seasonality. The firm still views BRINSUPRI®'s rapid launch and uptake as encouraging and believes the therapy is on track for blockbuster-level sales and remains well tolerated. Insmed closed at $121.51 on Sept 1, returned 25.42% over the past month, is down 13.45% over 52 weeks, and has a market capitalization of $27.14 billion. » More on finance.yahoo.com
Japan grants Insmed approval for lung drug Brensocatib

Japan’s Ministry of Health has approved BRINSUPRI (Brensocatib 25 mg) from Insmed for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 and older. The once-daily oral therapy is the first treatment approved in Japan for NCFB and complements existing approvals in the US and Europe. The decision is based on the phase-3 ASPEN study, which showed a reduction in pulmonary exacerbations and positive secondary endpoints over 52 weeks; common adverse events included COVID-19, nasopharyngitis, cough and headache. » More on de.investing.com
Insmed raises annual forecast after strong Brinsupri sales

Insmed reports strong Q2 figures and a jump in sales of its lung drug Brinsupri, whose revenue rose quarter-on-quarter by 48.7% to $309.2 million. In response, management raised the revenue outlook for 2026 to as much as $1.87 billion, thereby beating consensus estimates. The stock reacted with notable price gains and increased trading volume. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Insmed has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Insmed had revenue of €372.82M and net profit of -€11.6M

(EUR)	June 2026	YoY
Revenue	372.82M	309.09%
Gross profit	313.92M	366.36%
Net profit	-11.6M	95.75%
EBITDA	12.41M	104.92%

Fundamentals

Metric	Value
Market capitalization	€23.5B
Number of shares	216.75M
52-week high/low	€182.65 - €77.60
Dividends	No
Beta	0.82
P/E ratio	-30.73
PEG ratio	-1.22
P/B ratio	36.24
P/S ratio	24.06

Company profile

Insmed Incorporated, ein biopharmazeutisches Unternehmen, entwickelt und vermarktet Therapien für Patienten mit schweren und seltenen Krankheiten. Das Unternehmen bietet ARIKAYCE für die Behandlung von Mycobacterium avium complex-Lungenerkrankungen als Teil einer antibakteriellen Kombinationsbehandlung für erwachsene Patienten an. Außerdem entwickelt es Brensocatib, einen oralen reversiblen Inhibitor der Dipeptidylpeptidase 1 zur Behandlung von Patienten mit Bronchiektasen und anderen neutrophilen Erkrankungen, sowie Treprostinil Palmitil Inhalationspulver, eine inhalative Formulierung des Treprostinil-Prodrugs Treprostinil Palmitil zur Behandlung der pulmonalen arteriellen Hypertonie und anderer seltener Lungenerkrankungen. Insmed Incorporated wurde 1988 gegründet und hat seinen Hauptsitz in Bridgewater, New Jersey.